ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
Sep 22, 2026
DALLAS - Sept. 22, 2026 - PRLog -- ClearSight Therapeutics, Inc. Receives NIH SBIR Phase I Award for Research in Acute Infectious Conjunctivitis and EKC
Competitive federal award provides external scientific validation of the proposed research program and funds a disciplined path to new evidence
DALLAS, September 22nd, 2026 - ClearSight Therapeutics, Inc., a Dallas-based eye-care company, today announced that it has received a $306,852 Small Business Innovation Research Phase I award from the National Eye Institute, part of the National Institutes of Health. The competitive award marks a major scientific milestone for ClearSight and supports a one-year investigational research program involving a preservative-free ophthalmic formulation in acute infectious conjunctivitis and epidemic keratoconjunctivitis.
The project, award number R43EY039140, runs from September 15, 2026 through August 31, 2027. ClearSight Chief Scientific Officer Nuria Jimenez, PhD, PMP, will serve as principal investigator. The Notice of Award identifies the project as research and development and states that it does not support an NIH-defined clinical trial.
Why this award matters
NIH funding decisions follow rigorous peer review of scientific and technical merit and a second-level assessment of mission relevance. Reviewers consider the importance of the proposed research, the rigor and feasibility of the approach, and whether the investigators and organization have the expertise and resources to carry out the work. For ClearSight, the award provides meaningful external validation of the proposed scientific program and creates an accountable path for turning a promising research premise into credible evidence. It does not predetermine the results; it makes the disciplined work to generate those results possible.
"This award is a defining milestone for ClearSight. Following competitive review of the scientific and technical merit of our proposed work, NIH support gives us both meaningful external validation and non-dilutive capital to build the evidence base with rigor. It is a powerful vote of confidence in the importance of the question, the strength of the research plan, and our team's ability to execute."
Patrick Smale, Co-founder and Chief Executive Officer
"The questions at the center of this program matter to patients, clinicians, and the broader eye-care community. NIH support gives us the opportunity to investigate them with the rigor they deserve, generate credible data, and let the evidence guide what comes next. I am proud to lead this work alongside our team and collaborators."
Nuria Jimenez, PhD, PMP, Chief Scientific Officer and Principal Investigator
"I am excited and grateful for this initial support from the National Eye Institute, which represents an important step in advancing our innovation toward clinical development. This funding will enable us to generate the rigorous data needed to further validate the technology and its potential to address important unmet needs in topical ocular therapy. As a co-inventor and drug developer, I am particularly encouraged by the opportunity to translate this innovation into a product where patient safety, efficacy, and meaningful clinical benefit remain our highest priorities."
Suchismita Acharya, PhD, Co-Founder, Co-Inventor and Board Member
The SBIR program supports research and development by eligible small businesses. Beyond providing non-dilutive capital, the award gives ClearSight a structured milestone period through August 2027 and an accountable framework for translating a scientific premise into data. The work will proceed under a defined research plan, milestones, and federal reporting obligations.
Important regulatory context
ClearSight's NIH-funded research program will study preservative-free ophthalmic formulation in acute infectious conjunctivitis and EKC. This investigational research is separate from the labeled uses of any OTC lubricant eye drop marketed under M018 and does not establish safety, efficacy, or regulatory approval for treating either condition.
About ClearSight Therapeutics
ClearSight Therapeutics is a Dallas-based eye-care company founded in 2023 by industry veterans to develop accessible solutions for common ocular conditions. The company maintains distinct commercial and research programs, including OTC lubricant development under applicable monograph labeling and separately described investigational research. Learn more at clearsighttx.com.
NIH funding acknowledgment
Research reported in this release is supported by the National Eye Institute of the National Institutes of Health under Award Number R43EY039140. A total of $306,852, or 100% of the project, is financed with federal funds. A total of $0, or 0%, is financed with non-governmental funds. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Media contact
Patrick Smale
Co-founder & CEO
ClearSight Therapeutics
[email protected]
972-983-7761
Photos: (Click photo to enlarge)
Source: ClearSight Therapeutics, Inc.
Read Full Story - ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research | More news from this source
Press release distribution by PRLog
More News
King Charles' is getting livid with staffers: Internal row erupts over comment to Earl
King Charles’ is getting livid with staffers: Internal row erupts over comment to EarlThe hissed comment that sent social media into a spiral has just received an update by sources close to the King.The comment itself, “rest assured, we’ll forget soon enough!” is...
Taylor Swift leaves Swifties excited with cryptic clues and countdown clock
Taylor Swift leaves Swifties excited with cryptic clues and countdown clockTaylor Swift is no stranger to dropping easter eggs to her massive fanbase, who then get to work finding hidden clues.Now, she is apparently doing it again.First, her Instagram bio, which previously read 'show business for...
Saoirse Ronan's Bond villain dream turns awkward for her
Saoirse Ronan’s Bond villain dream turns awkward for herSaoirse Ronan dropped hints about Jack Lowden screen team-up.As the actress has said previously that she would love to consider the James Bond franchise specially as a villain.But now speaking with People magazine, she jokes that the...
Jordan Peele’s Monkeypaw Productions and Universal Film Team With American Cinematheque and Beyond Fest for ‘No Drama’ Initiative (EXCLUSIVE)
Jordan Peele’s Monkeypaw Productions is gearing up for the second edition of its “No Drama” filmmaker initiative, presented in partnership with Universal Film. The global initiative — developed by Universal’s Filmmaker & Content Strategies group — launched in 2024 as a one-year, non-exclusive program that supports emerging genre filmmakers by providing access and industry exposure […]
‘Darkwing Duck’ Reboot Ordered to Series at Disney+ With Mark Hamill, Seth Rogen in Lead Roles
The “Darkwing Duck” reboot has been ordered to series at Disney+, Variety has learned. The news comes nearly six years after Variety exclusively reported the project was in development at the streamer. The voice cast for the new series will include: Mark Hamill (“Batman: The Animated Series,” “Batman: Arkham Asylum”) as Drake Mallard aka Darkwing […]
Simon Cowell Will Miss ‘America’s Got Talent’ Season 21 Finale, Replacement Judge Revealed
Simon Cowell will not be returning to America’s Got Talent in time for the Season 21 finale. The 66-year-old longtime […] The post Simon Cowell Will Miss ‘America’s Got Talent’ Season 21 Finale, Replacement Judge Revealed appeared first on Just Jared - Celebrity News, Entertainment News & Photos.
‘Club Kid’ Gets 35mm Pre-Release Screening at San Francisco’s Castro Theatre – Film News in Brief
SFFilm will present a special preview screening A24’s “Club Kid” in 35mm at San Francisco’s Castro Theatre on Nov. 2 at 7:00 p.m. with writer, director and star Jordan Firstman making an appearance for a post-screening conversation. “’Club Kid’ is an exhilarating introduction to Jordan Firstman as a filmmaker, with a world that feels completely […]
Lionel Richie Recovering From “Common Procedure” For Atrial Fibrillation; Three Shows Canceled But Vegas Residency On Schedule
Lionel Richie is recovering from a procedure to address Atrial fibrillation, or an irregular heartbeat, and has canceled several shows over the next few weeks. The singer is still set to begin a Las Vegas residency next month. In a statement to the press, Richie’s rep said, “Lionel underwent a common procedure for Atrial fibrillation […]
‘America’s Got Talent’ Is Latest Reality Show To Eye California Exit
California is struggling to keep its iconic reality competition series filming in the Golden State after it emerged that another long-running series is considering an exit. America’s Got Talent is the latest show that may move production out of California for its next season, coming days after Deadline revealed that American Idol is on its […]
List Of Hollywood & Media Layoffs From Paramount To Warner Bros Discovery To CNN & More
Media layoffs across the entertainment industry are hitting hard after the past two years’ avalanche of job cuts. The unfortunate trend can still be felt following the Covid-19 pandemic, dual Hollywood strikes and — the latest event to hit Los Angeles hard: a series of wildfires that broke out in January 2025. As the entertainment […]
Sir Sean Connery's family plans new filmmaking centre in Edinburgh
It will be named after the James Bond actor, who worked as a milkman in the Scottish capital before becoming a Hollywood star.
From Jedward’s "Splashgate" To A Security Breach Lockdown: "Big Brother" Fans Are Hailing This The Best Season In Years
It's no surprise viewership is up 32 per cent from last year... View Entire Post ›
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.